Zinzino Sales Growth continues to impress as the Scandinavian direct selling giant reports a remarkable 58% year-over-year revenue increase for April 2025, reaching SEK 249.5 million. With strong international expansion and strategic acquisitions fueling momentum, Zinzino is clearly cementing its position as a leading force in the wellness and nutrition industry.
In April alone, Zinzino’s sales markets contributed SEK 249.5 million, compared to SEK 158.0 million in April 2024—a 58% rise. This impressive growth aligns with the company’s aggressive expansion strategy and its test-based nutritional product focus.
On the other hand, Faun Pharma, Zinzino’s manufacturing subsidiary, saw a decline in external sales, reporting SEK 6.2 million versus SEK 8.2 million the previous year.
Combining all units, the Zinzino Group posted total revenues of SEK 255.7 million for April—an overall increase of 54%.
In the other hand, Faun Pharma, Zinzino’s manufacturing subsidiary, saw a decline in external sales, reporting SEK 6.2 million versus SEK 8.2 million the previous year.
The cumulative revenue from January to April 2025 totaled SEK 979.4 million, up from SEK 620.7 million in the same period last year. This reflects a 58% YTD increase and sets the stage for a potentially record-breaking year.
North America: +237% (SEK 51.5M vs. 15.3M)
Asia-Pacific: +387% (SEK 26.3M vs. 5.4M)
South & West Europe: +70% (SEK 45.0M vs. 26.4M)
Central Europe: +44% (SEK 65.6M vs. 45.5M)
Some regions like East Europe and the Nordics experienced slight declines, but these were overshadowed by explosive growth elsewhere, particularly in the U.S., Mexico, India, and Southeast Asia.
The Zinzino is a publicly listed Scandinavian direct sales company specializing in test-based nutrition and cutting-edge skincare. With a rapidly growing global network, Zinzino leads the health and wellness industry through personalized, research-driven solutions.
For more details or to view the full April press release, visit zinzino.com.
obtain more details
There are no reviews yet. Be the first one to write one.
